2023年7月3日

11日美国股市抓住表现不佳的医疗保健部门发布了39分钟前我们寻找什么呢?加拿大的投资者主要关注国内市场,医疗保健部门可能构成挑战,因为它在TSX有限。与美国部门今年表现不佳,然而,只有2.2比较增加相比,标准普尔500指数15.1′年代比较,现在也许是一个时机来探索南部边界的投资机会。屏幕的市值超过50亿美元;StockPointer (SP)得分高于60 -分数主要考虑风险调整后的资本回报率,每股收益增长,每股自由现金流。0到100之间的分数不同。60分意味着一个高于平均水平的公司;相对经济表现指数大于0.6 - EPI相对是一个比较的计算一个公司的盈利能力与它的估值和资本成本。更高的盈利能力,较低的估值和较低的资本成本增加的比率;为了信息的目的,我们也包括三个月和12个月的NOPAT(税后净营业利润)增长,五年资本的自由现金流,为期一年的价格性能和股息收益率。 Please note that some ratios may be shown as of the end of the previous quarter. More about Inovestor Inovestor, a prominent Canadian fintech company with more than 20 years of experience, has partnered with Morningstar in an alliance, solidifying Inovestor’s unrivaled position as the industry’s leading alternative tool. To learn more visit our website . What we found Source: Inovester McKesson Corp. MCK-N , a diversified health-care company involved in products and services, has shown impressive growth, with 12-month and three-month NOPAT growth of 52 and 11.7 per cent, respectively. While the NOPAT surged, the share price rose by a reasonable 28.3 per cent. Additionally, the company has maintained an average free-cash-flow to capital of 12.5 per cent, the highest of our screen. These robust metrics have contributed to a significant SP score of 82. Biogen Inc. BIIB-Q , a well-known company in the biotechnology industry, has demonstrated vigorous growth in its NOPAT, with remarkable 12-month and three-month NOPAT growth of 62.9 and 4.6 per cent, respectively. The company’s relative EPI of 1.1 suggests a favorable trade-off between profitability, valuation and operating risks. The company has a P/E ratio of 13.1, the second among our screened companies, while its average free-cash-flow to capital stands at 12.1 per cent, ranking it as the second highest in our list. HCA Healthcare Inc. HCA-N is a prominent operator of health-care facilities. While the company has witnessed a slight decline of 3.6 per cent in its 12-month NOPAT, the market could view this as a short-term setback, considering the company’s impressive 71-per-cent increase in its share price over the past year. The three-month growth of 2.4 could confirm this investment thesis. Moreover, with a reasonable P/E ratio of 14.8, the company’s valuation remains favourable for investors who seek to establish a position after the price surge. The SP score stands at 83, the highest of our list. Investors are advised to do further research before investing in any of the companies listed in the accompanying table. Anthony Ménard, CFA, is vice-president of data management at Inovestor. For more details about these stocks, subscribe to the Inovestor for Advisors platform for free. Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today .